Louisbourg Investments Inc. Has $4.25 Million Position in Agilent Technologies, Inc. (NYSE:A)

Louisbourg Investments Inc. cut its holdings in Agilent Technologies, Inc. (NYSE:A) by 8.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 31,620 shares of the medical research company’s stock after selling 3,000 shares during the quarter. Louisbourg Investments Inc.’s holdings in Agilent Technologies were worth $4,248,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. AMF Tjanstepension AB bought a new stake in shares of Agilent Technologies in the 3rd quarter valued at about $2,726,000. Brookstone Capital Management grew its holdings in Agilent Technologies by 12.1% during the third quarter. Brookstone Capital Management now owns 1,903 shares of the medical research company’s stock valued at $283,000 after purchasing an additional 205 shares during the period. CWM LLC increased its stake in Agilent Technologies by 1.3% in the third quarter. CWM LLC now owns 11,491 shares of the medical research company’s stock valued at $1,706,000 after purchasing an additional 153 shares in the last quarter. Wesbanco Bank Inc. raised its holdings in Agilent Technologies by 8.4% in the third quarter. Wesbanco Bank Inc. now owns 2,455 shares of the medical research company’s stock worth $365,000 after purchasing an additional 190 shares during the period. Finally, Creative Planning boosted its position in shares of Agilent Technologies by 5.9% during the third quarter. Creative Planning now owns 44,910 shares of the medical research company’s stock worth $6,668,000 after purchasing an additional 2,498 shares in the last quarter. Institutional investors and hedge funds own 87.42% of the company’s stock.

Agilent Technologies Stock Down 1.3 %

A stock opened at $141.77 on Wednesday. The company has a market cap of $40.45 billion, a price-to-earnings ratio of 32.07, a P/E/G ratio of 4.00 and a beta of 1.07. Agilent Technologies, Inc. has a twelve month low of $124.16 and a twelve month high of $155.35. The business has a 50 day moving average price of $141.72 and a two-hundred day moving average price of $139.46. The company has a quick ratio of 1.58, a current ratio of 2.09 and a debt-to-equity ratio of 0.57.

Agilent Technologies (NYSE:A) last issued its earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.41 by $0.05. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The business had revenue of $1.70 billion during the quarter, compared to the consensus estimate of $1.67 billion. During the same period last year, the business posted $1.38 EPS. Agilent Technologies’s revenue was up .8% on a year-over-year basis. Analysts anticipate that Agilent Technologies, Inc. will post 5.56 EPS for the current fiscal year.

Agilent Technologies Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 22nd. Shareholders of record on Tuesday, December 31st were given a dividend of $0.248 per share. The ex-dividend date of this dividend was Tuesday, December 31st. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.24. This represents a $0.99 annualized dividend and a yield of 0.70%. Agilent Technologies’s dividend payout ratio (DPR) is 22.40%.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the completion of the sale, the chief executive officer now owns 39,652 shares of the company’s stock, valued at $5,947,800. The trade was a 4.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.26% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on A shares. Bank of America lowered their price objective on shares of Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. StockNews.com raised Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Citigroup boosted their price objective on Agilent Technologies to $165.00 and gave the company a “buy” rating in a research report on Thursday, December 19th. Wells Fargo & Company dropped their target price on shares of Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating on the stock in a report on Monday, December 9th. Finally, Sanford C. Bernstein dropped their price objective on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a report on Tuesday, November 26th. Seven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $144.38.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.